Merck subsidiary Inspire Pharmaceuticals has agreed to amend the payment terms of its AzaSite (azithromycin ophthalmic solution) 1% license agreement with InSite Vision.   On a quarterly basis, Merck will pay InSite a higher annual minimum royalty or the earned royalty for 2012 and 2013, as well as a catch-up payment for the difference between earned royalties paid for 4Q11, the first and second quarters of 2012, and the annual minimum royalties for those quarters.   The minimum royalties due to...